Sáb, Dic 30th 2023
The pharmaceutical company Roche is strengthening its diagnostics division with an acquisition.
The Basel-based company is taking over LumiraDx’s point-of-care diagnostics platform. This is to be fully integrated into Roche Diagnostics.
According to a press release issued on Friday evening, the transaction will cost Roche 295 million US dollars. There will also be an additional payment of up to 55 million. The transaction is expected to be completed in mid-2024.
The deal is part of Roche’s vision to enable patient-centered healthcare with point-of-care solutions. LumiraDx’s technology integrates multiple tests on one easy-to-use instrument. This offers patients more affordable and accessible tests.
©Keystone/SDA
Spanish 
English 
German 
French 
Arabic